By Anna Edney
- Advisory committee votes that shot’s benefit outweigh risks
- FDA, Pfizer bolster instructions for providers and recipients
Moderna Inc.’s Covid-19 vaccine won backing from a panel of experts who advise U.S. regulators, setting the stage for its shot to be the second vaccine cleared in the U.S. in as many weeks.
Food and Drug Administration advisers voted 20 to 0, with one abstention, on Thursday that the benefits of the vaccine outweigh any risk, giving a boost to efforts to ramp up the U.S. immunization campaign. The effort is initially focusing on health-care workers and seniors who live in long-term care facilities. The FDA could authorize the shot within the next day.
Moderna’s product is based on the same technology as a shot made by Pfizer Inc. and BioNTech SE that was cleared by the FDA last week, and like that vaccine showed a high degree of efficacy in late-stage clinical trials. At Thursday’s advisory meeting, some of the discussion focused on a handful of allergic reactions experienced by people in the U. S. and U.K. who got the Pfizer shot.